MDXHF Stock UPDATES Medx Health Corp (MDXHF) 0.0668 09/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medx Health Corp (MDXHF) 0.0668 $MDXHF

MedX Health Corp. Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 27, 8:04PM CDT
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX), dedicated to the early detection of skin cancer, announced its results for the three and six months ended June 30, 2014, which are also available on SEDAR (www.sedar.com).

MedX Health Corp. Announces Approval of Debt Settlement and AGM Results
Marketwire - Wed Jun 25, 9:40PM CDT
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that at its Annual and Special Meeting of Shareholders held on June 24, 2014, all resolutions proposed to shareholders were duly passed, including the approval of the issuance of 1,742,415 common shares relating to a settlement in November, 2013 of $435,603 of debt due to insiders of the Company. During the meeting, Gary Van Nest, David Hennigar, Steven Guillen, Ken McKay and Robert von der Porten were re-elected to the Board of Directors.

MedX Health Corp. Announces Extension of Private Placement
Marketwire - Mon Mar 24, 6:40PM CDT
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that it has extended, to April 11, 2014, the date for closing of a further tranche of the private placement of units ("Unit(s)" , in respect of which the first tranche, which raised $565,000, was closed on March 19, 2014. As previously, Trapeze Capital Corp., is acting as lead agent (the "Agent" . Each Unit comprises one common share and one share purchase warrant (a "Warrant" at $0.10 per Unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring two years following closing at $0.20 per share. MedX will pay the Agent a cash commission of 8% of cash raised, subject to a reduced rate in respect of subscribers on the "President's List", and will issue broker warrants to the Agent equal in number to 8% of the Units issued. Each broker warrant will be exercisable at $0.10 to acquire a unit comprising one common share and one share purchase warrant exercisable to acquire an additional common share from treasury at an exercise price of $0.20; the broker warrants and the share purchase warrants underlying the broker warrants will expire two years after the closing of the placement. Any shares comprised in the Units and the Warrants and any shares issued on exercise of the Warrants or the broker warrants or the share purchase warrants underlying the units in the broker warrants will be restricted from trading for a period of four months and one day from the date of closing of the issue.

MedX Health Corp. Announces Closing of First Tranche of Private Placement
Marketwire - Wed Mar 19, 5:16PM CDT
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that it has closed on a first tranche of a private placement, as previously announced on January 22, 2014. Trapeze Capital Corp., acted as lead agent (the "Agent" , to raise gross proceeds of up to $2.0 million, from accredited investors, on a reasonable efforts basis through a private placement of Units. The first tranche which was closed today, raised gross proceeds of $565,000 to its treasury by issuance of 5,650,000 units, comprising 5,650,000 common shares and 5,650,000 share purchase warrants ("Warrants" at $0.10 per unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring March 19, 2016, at $0.20 per share. The securities issued through the private placement were subscribed for by accredited investors, and are restricted from trading before July 20, 2014. At closing, MedX paid the Agent a cash commission of $24,200, and issued 452,000 broker warrants to the Agent. Each broker warrant will be exercisable at $0.10 to acquire a unit comprising one common share and one share purchase warrant exercisable to acquire an additional common share from treasury at an exercise price of $0.20; the broker warrants and the share purchase warrants underlying the broker warrants will expire on March 19, 2016. Any shares issued on exercise of the broker warrants or the share purchase warrants underlying the units in the broker warrants will be restricted from trading until July 20, 2014.

MedX Health Corp. Announces CE Mark for Its MOLEMATE(TM)/SIMSYS(TM) Skin Cancer Imaging Systems
Marketwire - Wed Feb 12, 10:50AM CST
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX), a leader in skin cancer imaging and diagnostics, announced receipt of a CE Mark from Conformite Europeenne, which allows the Company to market its MoleMate and SIMSYS systems in Europe to dermatologists and to expand further its pharmacy-based sales channel.

MedX Health Corp. Announces Brokered Private Placement
Marketwire - Wed Jan 22, 9:19AM CST
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces the engagement of Trapeze Capital Corp., as lead agent (the "Agent" , to raise gross proceeds of up to $2.0 million, from accredited investors, on a reasonable efforts basis through a private placement of Units, with each Unit comprised of one Common Share and one Common Share Purchase Warrant ('Warrant" (the "Offering" at $0.10 per Unit. Each Warrant will entitle the holder to purchase one Common Share during the period ending two years from the date of issue, at an exercise price of $0.20.

MedX Health Corp. Announces Closing of Private Placement and Debt Settlements
Marketwire - Tue Dec 31, 5:03PM CST
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that it has closed on a private placement, as announced on December 20, 2013, to raise $203,000 by the issuance of 2,030,000 units, comprising 2,030,000 common shares and 2,030,000 share purchase warrants ("Warrants" at $0.10 per unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring December 31, 2014, at $0.20 per share. The securities issued through the private placement were subscribed for by accredited investors, and are restricted from trading before May 1, 2014.

MedX Health Corp. Announces Proposed Private Placement to Raise $203,000
Marketwire - Fri Dec 20, 3:36PM CST
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that it has entered into private placement agreements with accredited investors to raise a total of $203,000 by issuance of a total of 2,030,000 Units at $0.10 per unit. Each Unit comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at the price of $0.20 during the period expiring December 31, 2014. Closing of the Placement is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.

MedX Health Corp. results for the Second Quarter of fiscal 2013
CNW Group - Tue Aug 27, 10:06PM CDT
TSX Venture Symbol: MDX

MedX Health Corp. Announces Share Issuance Pursuant To Debt Settlement Agreements And Also Grant Of Stock Options
CNW Group - Fri Jul 19, 3:51PM CDT
TSX Venture Symbol: MDX

MedX Health Corp. reaches agreements to settle debts of $362,078
CNW Group - Thu Jul 04, 2:23PM CDT
TSX Venture Symbol: MDX CUSIP #: 585090

MedX Health Reports 2012 and First Quarter 2013 Financial Results
CNW Group - Fri Jun 07, 11:29AM CDT
MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy for tissue repair and pain relief have reported their revenues for 2012 and the first quarter of 2013. Please see www.SEDAR.com for the actual filings.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading